Abstract 3190

Introduction:

Cardiac complications mainly related to myocardial iron overload (MIO) remain the main cause of morbidity and mortality in thalassemia major (TM). Thalassemia cardiomyopathy is treatable and partly reversible if appropriate chelation therapy is instituted in time. The validated multislice multiecho T2* Cardiovascular Magnetic Resonance (CMR) technique has permitted to quantify segmental and global myocardial iron burden detecting different patterns of iron overload. The aim of this study was to verify the risk of cardiac complications related to different patterns of MIO in a large cohort of TM patients.

Methods:

We considered 812 TM patients for who CMR and cardiac data were collected in a central data base. Three short-axis views (basal, medium, apical) of the left ventricle were acquired using a multislice multiecho T2* sequence. Using a previously validated software the 16 segmental T2* values and the mean global heart T2* value were provided. A conservative cut off of 20 ms was considered the limit of normal for the segmental and global T2* values.

Results:

We identified 4 groups of patients: group I (17%) with homogeneous MIO (all segments with T2*<20 ms), group II (12%) with heterogeneous MIO (some segments with T2*<20 ms and others with T2*≥20 ms) and global heart T2*<20 ms; group III (29%) with heterogeneous MIO and global heart T2*≥20 ms; group IV (42%) with no MIO (all segments with T2*≥20 ms). The clinically relevant findings in the 4 groups are summarized in Table 1. The percentage of patients with cardiac complications was significantly different in the 4 groups (P<0.0001). In particular, the percentage of patients with heart failure was significantly different in the 4 groups (P<0.0001). No significant differences were found among groups in the percentage of arrhythmias and pulmonary hypertension. Odds Ratio for cardiac complications was 1.7 (1.0–2.7 OR 95% CI; P=0.041) for patients with homogeneous MIO versus patients with no MIO. Odds Ratio for heart failure was 2.3 (1.3–4.2 OR 95% CI; P=0.004) for patients with homogeneous MIO versus patients with no MIO and 2.2 (1.1–4.2 OR 95% CI; P=0.020) for patients with heterogeneous MIO and global heart T2*<20 ms versus patients with no MIO.

Table 1
Homogeneous MIO (N=138)Heterogeneous MIO and global heart T2*<20 ms (N=97)Heterogeneous MIO and global heart T2* ≥20 ms (N=238)No MIO (N=339)P
Sex (M/F) 67/71 38/59 119/119 157/172 0.304 
Age (years) 28.9 ± 7.4 30.8 ± 7.4 30.4 ± 8.9 31.1 ± 8.9 0.069 
Hemoglobin (g/dl) 9.7 ± 0.6 9.6 ± 0.5 9.7 ± 0.6 9.6 ± 0.8 0.309 
Serum ferritin (ng/l) 2454 ± 1969 2043 ± 1796 1328 ± 1277 1114 ± 1004 <0.0001 
Cardiac disease, n (%) 34 (24.6) 20 (20.6) 20 (8.4) 56 (16.5) <0.0001 
Heart failure, n (%) 24 (17.4) 16 (16.5) 10 (4.2) 28 (8.3) <0.0001 
Arrhythmias, n (%) 13 (9.4) 6 (6.2) 8 (3.4) 23 (6.8) 0.112 
Pulm. hypertension, n (%) 3 (2.2) 1 (1.0) 4 (1.7) 14 (4.1)  
Homogeneous MIO (N=138)Heterogeneous MIO and global heart T2*<20 ms (N=97)Heterogeneous MIO and global heart T2* ≥20 ms (N=238)No MIO (N=339)P
Sex (M/F) 67/71 38/59 119/119 157/172 0.304 
Age (years) 28.9 ± 7.4 30.8 ± 7.4 30.4 ± 8.9 31.1 ± 8.9 0.069 
Hemoglobin (g/dl) 9.7 ± 0.6 9.6 ± 0.5 9.7 ± 0.6 9.6 ± 0.8 0.309 
Serum ferritin (ng/l) 2454 ± 1969 2043 ± 1796 1328 ± 1277 1114 ± 1004 <0.0001 
Cardiac disease, n (%) 34 (24.6) 20 (20.6) 20 (8.4) 56 (16.5) <0.0001 
Heart failure, n (%) 24 (17.4) 16 (16.5) 10 (4.2) 28 (8.3) <0.0001 
Arrhythmias, n (%) 13 (9.4) 6 (6.2) 8 (3.4) 23 (6.8) 0.112 
Pulm. hypertension, n (%) 3 (2.2) 1 (1.0) 4 (1.7) 14 (4.1)  
Conclusions:

Homogeneous MIO predicts a significantly higher risk to develop cardiac complications, especially heart failure, suggesting an intensive chelation therapy in this group of patients.

Disclosures:

No relevant conflicts of interest to declare.

This icon denotes a clinically relevant abstract

Author notes

*

Asterisk with author names denotes non-ASH members.